Fundraising Fox
/Companies
Sign in

Havah Therapeutics

Longmont, US · Founded 2023 · Delaware corporation

Find your way into Havah Therapeutics

Sign up to see every warm intro you have to Havah Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Havah Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

HavaH Therapeutics develops T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole, aimed at preventing and treating hormone receptor positive breast cancer, including ductal carcinoma in situ (DCIS) and ER+ disease. The clinical-stage company targets the intra-mammary hormonal balance to slow tumor growth and reduce the need for surgery.

BiotechDeep TechHealthtech

Founders & leadership

Havah Therapeutics was founded in 2023 by Stephen N Birrell.

SNStephen N Birrell
Stephen N BirrellFounder & AdvisorDr. Stephen Birrell is a Fellow of the Royal Australasian College of Surgeons with over 30 years of experience in breast oncology and medical research. He founded Havah Therapeutics and Wellend Health, an Australian breast health clinic, and holds patents related to breast cancer risk reduction and aromatase inhibitor therapies.
MBMatt Brewer
Matt BrewerCEO & PresidentMatt Brewer is CEO and President of Havah Therapeutics, a clinical-stage company developing T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole for hormone receptor positive breast cancer treatment and prevention.
JA
John AdairCFO
RM
Ronald MartellNamed on SEC filing
JWJim Weiss
Jim WeissBoard Member and Investor

Reported raises · per SEC filings

Form D private placements

$507.4K disclosed across 1 round · 2024

▶$507.4KraisedMay 2024 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ronald MartellDirector
  • Matthew BrewerExecutive Officer, Director
  • Jim WeissDirector
Offering amount
$507.4K
Amount sold
$507.4K
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Havah Therapeutics do?
HavaH Therapeutics develops T+Ai, a subcutaneous extended-release pellet combining testosterone and anastrozole, aimed at preventing and treating hormone receptor positive breast cancer, including ductal carcinoma in situ (DCIS) and ER+ disease. The clinical-stage company targets the intra-mammary hormonal balance to slow tumor growth and reduce the need for surgery.
Who founded Havah Therapeutics?
Havah Therapeutics was founded by Stephen N Birrell in 2023.
How much funding has Havah Therapeutics raised?
Havah Therapeutics has disclosed $507.4K raised across 1 round.
Where is Havah Therapeutics headquartered?
Havah Therapeutics is headquartered in Longmont, US.